Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.69 |
| ▸ | PTPRA | P18433 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | PTPRC | P08575 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.45 |
| ▸ | PTPRB | P23467 | 2/20 | 0.45 |
| ▸ | PTPRE | P23469 | 2/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914236 | 0.88 | FLT3 (0.70) | PTPN1PTPRAFLT3KDM4EHSD17B10 | |
| SCHEMBL27415542 | 0.86 | KDM4E (0.51) | PTPN1PTPRAFLT3KDM4EHSD17B10 | |
| SCHEMBL4079889 | 0.84 | PTPN1 (0.66) | PTPN1PTPRACNR2PTPRCPTPN2 | |
| SCHEMBL21597480 | 0.82 | MAPT (0.60) | KDM4EHSD17B10MAPTCNR2ALDH1A1 | |
| SCHEMBL22372483 | 0.82 | PTPN1 (1.00) | PTPN1PTPRACNR2PTPRCPTPN2 | |
| SCHEMBL3914277 | 0.82 | FLT3 (0.77) | PTPN1FLT3KDM4EHSD17B10MAPT | |
| SCHEMBL5453432 | 0.78 | PTPN1 (0.71) | PTPN1FLT3KDM4EHSD17B10MAPT | |
| SCHEMBL4136651 | 0.78 | PTPN1 (0.69) | PTPN1PTPRAMAPTCNR2PTPRC | |
| SCHEMBL5741223 | 0.77 | FLT3 (0.69) | PTPN1FLT3KDM4EHSD17B10MAPT | |
| SCHEMBL21597466 | 0.75 | KDM4E (0.53) | PTPN1FLT3KDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | PTPN1 195/4885PTPRA 231/4885FLT3 3722/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | PTPN1 195/4885PTPRA 231/4885FLT3 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.